Vaccine Implementation Project
AIM's Vaccine Implementation Project aims to improve readiness and implementation of new immunization products and changes to existing recommendations in the U.S.
Understanding Historical Partner Engagement in U.S. Vaccine Implementation: An Environmental Scan to Guide Future Planning to Support Immunization Programs Poster
This AIM poster was displayed at the 2026 NAIIS Meeting and examines partner engagement to implement vaccine recommendations.
2025 AIM Annual Survey of Federally Funded Immunization Programs Poster
This AIM poster was displayed at the 2026 NAIIS Meeting and highlights a portion of the results from the 2025 AIM Annual Survey.
2025 AIM Annual Survey Aggregate Report
View the 2025 AIM Annual Survey Aggregate Report. The response rate for 2025 was 96% with 63 of 66 IPs completing the survey.
2025 AIM Annual Survey
Find resources on AIM's 2025 Annual Survey, including a webinar focused on unpacking survey insights and a snapshot with high-level visual information.
2025 Annual Survey Snapshot
The 2025 AIM Annual Survey Snapshot is a high-level overview of the results of the 2025 Annual Survey. The snapshot contains easy-to-read data.
2024 AIM Annual Survey
AIM’s 2024 annual survey assessed and characterized IP policy, infrastructure, program activities, priorities, and the impact of funding changes on IPs.
Manuscript: A survey of state and local practices encouraging pediatric COVID-19 vaccination of children ages 6 months through 11 years
In AIM’s first collaborative article with CDC, this manuscript highlights state and local practices optimizing the pediatric COVID-19 vaccination program.
Increasing Equitable Access to Birth Dose Immunizations
This tip sheet provides a list of actionable solutions to challenges IPs and partners may face in increasing equitable access to birth dose immunizations.
Observations from Listening Sessions with AIM Members
AIM conducted listening sessions to gather lessons learned from the pediatric COVID-19 vaccine roll-out for children ages 5-11.